Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Checkpoint Therapeutics, Inc.NONE · Entity 78931 | Interim CFO | September 09, 2016 | October 04, 2016 |
| Jones Ventures INTL Acquisition1 CorpJONE · Entity 9391 | Director | July 13, 2026 | July 17, 2026 |
| MUSTANG BIO, INC.NONE · Entity 8350 | Interim CFO | September 26, 2016 | June 30, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Checkpoint Therapeutics, Inc.
Report date September 09, 2016 · Filed October 04, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (Restricted)SEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2016-09-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Jones Ventures INTL Acquisition1 Corp
Report date July 13, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 30,000 |
Reported balance
After 2026-07-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-13 · Other · Acquired 30,000 · Balance 30,000 F1: The Class B ordinary shares are automatically convertible into the shares of the Issuer's Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The Class B ordinary shares are subject to forfeiture under certain circumstances relating to Mr. Horin's service on the Issuer's Board of Directors. F2: 2. As contemplated by the securities purchase agreement between Jones Ventures INTL Acquisition1 Sponsor, LLC (the "Sponsor") and Mr. Horin, dated July 13, 2026, the Sponsor assigned 30,000 Class B ordinary shares to Mr. Horin in connection with Mr. Horin's appointment to the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B ordinary shares are automatically convertible into the shares of the Issuer's Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The Class B ordinary shares are subject to forfeiture under certain circumstances relating to Mr. Horin's service on the Issuer's Board of Directors.
F2: 2. As contemplated by the securities purchase agreement between Jones Ventures INTL Acquisition1 Sponsor, LLC (the "Sponsor") and Mr. Horin, dated July 13, 2026, the Sponsor assigned 30,000 Class B ordinary shares to Mr. Horin in connection with Mr. Horin's appointment to the Issuer's Board of Directors.
MUSTANG BIO, INC.
Report date September 26, 2016 · Filed June 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (Restricted)SEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2016-09-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 13, 2026 Filed Jul 17, 2026 23:25 UTC | Jones Ventures INTL Acquisition1 Corp JONE · Entity 9391 | OtherClass B Ordinary Shares · Derivative | 30,000 | $0.00 | $90.00 |
DisclosureSEC source: 0001213900-26-079339 · ownership.xml · derivative · entry 1 Horin David J · CIK 0001429468 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Class A Ordinary Shares · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: The Class B ordinary shares are automatically convertible into the shares of the Issuer's Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The Class B ordinary shares are subject to forfeiture under certain circumstances relating to Mr. Horin's service on the Issuer's Board of Directors. F2 · kind: 2. As contemplated by the securities purchase agreement between Jones Ventures INTL Acquisition1 Sponsor, LLC (the "Sponsor") and Mr. Horin, dated July 13, 2026, the Sponsor assigned 30,000 Class B ordinary shares to Mr. Horin in connection with Mr. Horin's appointment to the Issuer's Board of Directors. F1 · derivative.exercise_date: The Class B ordinary shares are automatically convertible into the shares of the Issuer's Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The Class B ordinary shares are subject to forfeiture under certain circumstances relating to Mr. Horin's service on the Issuer's Board of Directors. F1 · derivative.expiration_date: The Class B ordinary shares are automatically convertible into the shares of the Issuer's Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The Class B ordinary shares are subject to forfeiture under certain circumstances relating to Mr. Horin's service on the Issuer's Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.